“PEG-MGF” is not a complete molecular identity. A defensible material record must define the peptide, PEG architecture, attachment chemistry, site distribution and unmodified-peptide fraction.
Evidence at a glance
- PEGylation changes apparent size, chromatography and ionization, so a single nominal molecular weight is inadequate.
- PEG polydispersity and multiple attachment sites can create a distribution rather than one discrete analyte.
- Native MGF in a PEGDMA hydrogel is a delivery formulation, not a chemically PEGylated peptide.
Identity record
Conventional reversed-phase HPLC may not resolve every polymer-related species, while mass spectrometry can be complicated by a PEG mass distribution. Orthogonal methods and well-characterized standards are therefore important.
Analytical and evidence boundary
The material name should not borrow a sequence, mass or half-life from native MGF, IGF-1Ec or another supplier without direct documentation. PEGylation behavior depends on the exact construct.
FDA’s absence-of-human-exposure statement is a safety boundary, not a claim that a particular catalog sample has been tested. Lot documentation must still establish identity and quality independently.
Editorial rule
State the exact material, form, model or population and endpoint supported by the cited record. Do not convert mechanistic plausibility, an animal result, an official finished-drug label or an analytical test into a claim about an unrelated catalog lot.
Sources & editorial method
This article discusses the source records listed below, with the study models and limitations stated alongside the findings. AI-assisted drafting and image generation were used. The reference list identifies the records behind this article; it is not an independent peer review or verification of a supplied catalog lot.
5 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, sample size, model/population limits, finished-drug scope, regulatory status and product-evidence boundaries are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- MGF E peptide showed no apparent myoblast effectNull cell and primary muscle-stem-cell study; PMID 24253050.
- MGF peptide delivery from PEGDMA microrodsBiomaterials delivery study using native MGF in a PEGDMA matrix; PMID 24908137.
- Localized MGF E-domain delivery after mouse myocardial infarctionMouse cardiac delivery study using peptide-eluting polymeric microstructures; PMID 25678113.
- Certain Bulk Drug Substances That May Present Significant Safety RisksU.S. FDA. Current compounding safety-information page.
- WADA 2026 Prohibited ListOfficial list prohibits mechano growth factors.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
